/INDP
INDP Stock - Indaptus Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$2.03-3.79%
$0.08 (-3.79%) • Dec 19
50
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.78
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $2.23
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for INDP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.01 – $2.05
TARGET (TP)$2.33
STOP LOSS$1.87
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.04
52W High$47.60
52W Low$1.65
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-15,365,751 | $-16,378,474 | $-14,910,906 | $-7,729,108 | $-3,599,265 |
| Net Income | $-15,022,027 | $-15,423,471 | $-14,322,798 | $-7,711,386 | $-3,584,151 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.61 | $-1.84 | $-1.73 | $-1.89 | $-0.66 |
Company Overview
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
INDPBeat Rate
75%
Last 20 quarters
Avg Surprise
+7.6%
EPS vs Estimate
Beats / Misses
15/5
Last 12 quarters
Latest EPS
$-2.98
Q4 2025
EPS Surprise History
Q1 24
+13.0%
$-0.47vs$-0.54
Q2 24
+21.1%
$-0.45vs$-0.57
Q3 24
+13.0%
$-0.47vs$-0.54
Q4 24
+31.9%
$-0.32vs$-0.47
Q1 25
+7.3%
$-0.38vs$-0.41
Q2 25
+22.0%
$-8.96vs$-11.48
Q3 25
+1.6%
$-9.09vs$-9.24
Q4 25
+28.5%
$-2.98vs$-4.17
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 12, 2025 | $-4.17 | $-2.98 | +28.5% | ✓ BEAT |
Q3 2025 | Aug 13, 2025 | $-9.24 | $-9.09 | +1.6% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-11.48 | $-8.96 | +22.0% | ✓ BEAT |
Q1 2025 | Mar 13, 2025 | $-0.41 | $-0.38 | +7.3% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.47 | $-0.32 | +31.9% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-0.54 | $-0.47 | +13.0% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-0.57 | $-0.45 | +21.1% | ✓ BEAT |
Q1 2024 | Mar 13, 2024 | $-0.54 | $-0.47 | +13.0% | ✓ BEAT |
Q4 2023 | Nov 6, 2023 | $-0.55 | $-0.47 | +14.5% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.58 | $-0.39 | +32.8% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.59 | $-0.51 | +13.6% | ✓ BEAT |
Q1 2023 | Mar 17, 2023 | $-0.52 | $-0.44 | +15.4% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.47 | $-0.42 | +10.6% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-0.43 | $-0.46 | -7.0% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.39 | $-0.41 | -5.1% | ✗ MISS |
Q1 2022 | Mar 21, 2022 | $-0.90 | $-0.22 | +75.6% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $-0.55 | $-0.81 | -47.3% | ✗ MISS |
Q3 2021 | Aug 16, 2021 | $-2.56 | $-5.53 | -116.0% | ✗ MISS |
Q2 2021 | May 17, 2021 | $-3.48 | $-3.84 | -10.3% | ✗ MISS |
Q1 2021 | Mar 16, 2021 | $-3.40 | $-2.12 | +37.6% | ✓ BEAT |
Latest News
Indaptus Therapeutics Q3 EPS $(2.98) Beats $(4.17) Estimate
📈 PositiveBenzinga•Nov 12, 2025, 01:35 PM
Indaptus Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 109.76%
📈 PositiveBenzinga•Sep 26, 2025, 04:45 PM
Indaptus Therapeutics Shares Resume Trade
➖ NeutralBenzinga•Sep 26, 2025, 04:38 PM
Indaptus Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 77.13%
📈 PositiveBenzinga•Sep 26, 2025, 04:33 PM
Indaptus Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 50.91%
📈 PositiveBenzinga•Sep 26, 2025, 04:22 PM
Indaptus Therapeutics shares are trading lower. The company announced recent updates for its ongoing INDP-D101 clinical trial.
📉 NegativeBenzinga•Sep 5, 2025, 12:49 PM
Indaptus Therapeutics shares are trading lower. The company announced recent updates for its ongoing INDP-D101 clinical trial.
📉 NegativeBenzinga•Sep 4, 2025, 08:41 PM
Indaptus Reports Partial Response From Decoy20 Monotherapy In Urothelial Cancer; Combo With PD-1 Inhibitor Shows Favorable Safety
📈 PositiveBenzinga•Sep 4, 2025, 08:02 PM
Indaptus Therapeutics to execute 1-for-28 reverse stock split
📉 NegativeSeeking Alpha•Jun 25, 2025, 11:57 AM
Frequently Asked Questions about INDP
What is INDP's current stock price?
Indaptus Therapeutics, Inc. (INDP) is currently trading at $2.03 per share. The stock has moved -3.79% today.
What is the analyst price target for INDP?
No analyst price targets are currently available for this stock.
What sector is Indaptus Therapeutics, Inc. in?
Indaptus Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is INDP's market cap?
Indaptus Therapeutics, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does INDP pay dividends?
No, Indaptus Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATXI
Avenue Therapeutics, Inc.
$0.65
Mkt Cap: $0.0B
AZTR
Azitra, Inc.
$0.29
Mkt Cap: $0.0B
GTBP
GT Biopharma, Inc.
$0.76
Mkt Cap: $0.0B
LIPO
Lipella Pharmaceuticals Inc.
$0.21
Mkt Cap: $0.0B
NKGN
NKGen Biotech, Inc. Common Stock
$0.05
Mkt Cap: $0.0B
PBM
Psyence Biomedical Ltd.
$1.00
Mkt Cap: $0.0B
PTIX
Protagenic Therapeutics, Inc.
$1.19
Mkt Cap: $0.0B
REVB
Revelation Biosciences, Inc.
$0.89
Mkt Cap: $0.0B
SLRX
Salarius Pharmaceuticals, Inc.
$0.69
Mkt Cap: $0.0B
SLXN
Silexion Therapeutics Ltd.
$2.40
Mkt Cap: $0.0B
Explore stocks similar to INDP for comparison